$25.36
-1.1%Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Last Annual Value
125.00B
3-Year CAGR
10%
5-Year CAGR
10%
10-Year CAGR
4%
| Company | Goodwill and Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Pfizer Inc. NYSE:PFE | 125.00B | -2.0% | 10.9% | 1.6% | |
![]() Amgen Inc. NASDAQ:AMGN | 40.96B | -7.2% | 6.4% | 5.0% | |
![]() Merck & Co., Inc. NYSE:MRK | 48.26B | 7.2% | 1.8% | 3.1% | |
![]() Bristol-Myers Squibb Company NYSE:BMY | 40.86B | -5.7% | -8.4% | 17.3% | |
![]() Stryker Corporation NYSE:SYK | 24.97B | 8.0% | 7.1% | 9.7% | |
![]() Danaher Corporation NYSE:DHR | 60.97B | -0.7% | -1.0% | 5.5% | |
![]() Gilead Sciences, Inc. NASDAQ:GILD | 25.29B | -10.1% | -9.6% | 9.6% | |
![]() Boston Scientific Corporation NYSE:BSX | 25.30B | 7.5% | 6.9% | 7.3% |
Continue your PFE research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.